Varenicline reduced smoking behaviour in a mentally ill person

Abstract

Get full access to this article

View all access options for this article.

References

Coe JW Brooks PR Vetelino MG Wirtz MC Arnold EP Huang J (2005a) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474–3477.

Green MF (2006) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67: 3–8.

Hughes JR Hatsukami DK Mitchell JE Dahlgreen LA (1986) Prevalence of smoking among psychiatric outpatients. Am J Psych. 143: 993–997.

Jorenby DE Hays JT Rigotti NA Azoulay S Watsky EJ Williams KE (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56–63.

Montgomery SA Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.

Ochoa ELM Lasalde-Dominicci J (2007) Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell. Mol Neurobiol 27: 609–639.

Pomerleau CS Carton SM Lutzke ML Flessland KA Pomerleau OF (1994) Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. Addict Behav 19: 33–39.

Purdon SE (2005) The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties. PNL Inc, Edmonton, Alberta, Canada.